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ABSTRACT 
Hyperhomocysteinemia is a risk factor for Alzheimer’s disease (AD). Both homocysteine and 
Aβ, which accumulates in the brain of AD patients, bind copper. Aim of this study was to test 
the hypothesis that the association of homocysteine and AD results from a molecular 
interaction between homocysteine and Aβ that is mediated by copper. We established a 
microtiter plate format thioflavin T aggregation assay to monitor Aβ42 fibrillization. Copper (5 
µM) completely prevented Aβ42 (5 µM) fibrillization. Homocysteine in the absence of copper 
did not impact Aβ42 fibrillization, but physiological concentrations of homocysteine (10-100 
µM) attenuated the inhibitory effect of copper on Aβ42 fibril formation. These results were 
qualitatively confirmed by electron microscopy, which did not reveal morphological 
differences. To compare the toxicity of fibrillar and non-fibrillar Aβ42 exposed to copper or 
homocysteine, rat primary cortical neurons were treated in vitro with 5 µM Aβ42 for 72 hours. 
After incubation with 5 µM Aβ42 that had been aggregating in the absence of homocysteine 
or copper, cell viability was reduced to 40%. Incubation with 5 µM Aβ42, in which fibril 
formation had been prevented or reverted by the addition of 5 µM copper, resulted in cell 
viability of approximately 25%. Accordingly, viability was reduced to 25% after incubation 
with 5 µM monomeric, i.e. non-fibrillized, Aβ42. The addition of homocysteine plus copper to 
5 µM Aβ42 yielded 50% viability. In conclusion, copper prevents and reverts Aβ fibril 
formation leading rather to formation of lower order oligomers or amorphous aggregates, and 
homocysteine reduces these effects. Such mechanisms may explain the association of 
hyperhomocysteinemia and AD, leading to novel therapeutic strategies in the prevention and 
treatment of this disease.  
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INTRODUCTION 
Alzheimer’s disease (AD) is a multifactorial neurodegenerative condition constituting the 
majority of dementias. Primary feature of AD is neuronal cell loss in the hippocampus and 
cerebral cortex, areas involved in memory and cognition (Bernardo et al., 2007; Kim et al., 
2008). Histopathological characteristics are depositions of amyloid plaques, comprising 
extracellular accumulations of fibrillar amyloid β-peptide (Aβ), and the formation of 
intracellular neurofibrillary tangles composed of hyperphosphorylated tau (P-tau) (Hooijmans 
et al., 2009; Kim and Tsai, 2009). Aβ is produced by cleavage of the amyloid precursor 
protein (APP) by -secretase (BACE-1) and -secretase, which is comprised of four proteins: 
presenilin (PS) -1 or -2, PEN, Aph-1 and Nicastrin. Cleavage of APP by -secretase results 
in a N-terminal soluble fragment and a C-terminal fragment that is further cleaved by -
secretase resulting in Aβ peptides. Missense mutations in either APP or PS-1 can cause 
accumulation of Aβ in hereditary AD. The mechanism leading to Aβ accumulation in the 
majority of sporadic AD patients is unclear (Mare et al., 2007). Extracellular aggregation of 
the Aβ-peptide is considered a central and causative phenomenon of AD (Yoshiike et al., 
2001; Hooijmans et al., 2009; Zatta et al., 2009; Finder et al., 2010). However, in AD 
patients, Aβ is also present in elevated amounts within the degenerating neurons, and this 
may contribute to cell death (Hasegawa et al., 2005).  
In vivo Aβ has two predominant forms: Aβ1-40 and Aβ1-42 with two additional hydrophobic 
residues at the carboxyterminus. Aβ1-40 is the main soluble species, whereas Aβ1-42 is the 
predominant species found in amyloid plaques. The latter is more toxic to neurons and is 
considered the most amyloidogenic species, most likely responsible for the neuropathology 
in AD (Hasegawa et al., 2005; Mare et al., 2007; Finder et al., 2010). Aβ aggregation is 
believed to happen in phases: First, Aβ monomers associate into soluble oligomers that then 
form insoluble oligomers (initial slow nucleation or “seeding”), generating protofibrils, and 
fibrils (Finder and Glockshuber, 2007; Tougu et al., 2009).  
 4 
Whether Aβ forms fibrils in vitro in the presence of copper and the nature of these fibrils is 
currently a subject of debate. Main question is the accelerating or preventing role of copper 
in amyloid fibril formation, and whether this role is dependent on Cu2+ or Aβ concentration 
and stoichiometry. It has been presented that sub-stoichiometric concentrations of Cu2+ 
accelerate amyloid fibril formation, and supra-stoichiometric concentrations of Cu2+ prevent 
fibrillization (Viles, 2012). There are several studies where Cu2+ was reported to inhibit fibril 
formation and rather form amorphous aggregates (Yoshiike et al., 2001; Raman et al., 2005; 
Tougu et al., 2009; Innocenti et al., 2010). On the contrary, the opposing arguments rely 
mainly on the study of (Sarell et al., 2010) where the substoichiometric levels of Cu2+ were 
shown to accelerate fibril formation of Aβ. A recent study of (Mold et al., 2013) addresses this 
dilemma by fluorimetry and transmission electron microscopy. In this study they show that 
Cu2+, independent of stoichiometry, prevented the formation of ThT-positive amyloid fibrils of 
Aβ42.                
Amyloid plaques are composed of fibrillar Aβ, small amounts of other proteins and transition 
metals like copper and zinc (Tougu et al., 2009). Several studies have shown that 
homeostasis of the transition metals copper and zinc can greatly influence Aβ misfolding and 
plaque formation. Furthermore, restoring metal ion homeostasis dissolved Aβ plaques in 
mice and delayed cognitive deficits in AD patients (Zatta et al., 2009). Thus, an interaction 
between Aβ and copper may be involved in AD pathology (Klevay, 2007b; a).  
We have previously shown that homocysteine (Hcy) binds copper, and that this may be an 
important mechanism of the neurotoxicity of Hcy, as the presence of Hcy can lead to 
deficiency of copper-dependent enzymes like cytochrome-C-oxidase (White et al., 2001; 
Apostolova et al., 2003; Linnebank et al., 2006). Hcy is a non-proteinogenic sulfhydryl-
containing amino acid formed as an intermediate in the metabolism of methionine 
(Hasegawa et al., 2005; Bernardo et al., 2007; Kim et al., 2008). Deficiencies of vitamin B12 
or folate, common conditions in the elderly, can lead to hyperhomocysteinemia, which is a 
risk factor for cardio- and cerebrovascular diseases as well as neurodegenerative disorders 
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such as AD (White et al., 2001; Irizarry et al., 2005; Linnebank et al., 2006; Bernardo et al., 
2007; Kim et al., 2008). In hyperhomocysteinemic patients, blood copper levels are elevated, 
possibly due to binding to increased amounts of Hcy (Apostolova et al., 2003; Linnebank et 
al., 2006). In cell culture, Hcy sensitises neurons to Aβ toxicity by induction of intraneuronal 
Aβ accumulation due to speculative mechanisms (Hasegawa et al., 2005). In addition, 
hyperhomocysteinemia increases Aβ production in rats, probably through enhanced 
expression of -secretase and APP phosphorylation, placing hyperhomocysteinemia 
upstream of increased Aβ production (Zhang et al., 2009). In this study, we aimed at 
modelling the interaction between copper, Hcy and Aβ fibril formation.  
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Materials and Methods 
Origin of reagents  
All reagents were ultra pure quality and purchased from Sigma-Aldrich (Buchs, Switzerland) 
unless otherwise indicated. DL-Homocysteine was minimum 95% titration (Sigma-Aldrich). 
Recombinant Aβ42 peptide was purchased as a HFIP (1,1,1,3,3,3-hexafluoro-2-propanol) 
film, and H6A mutated recombinant Aβ42 and scrambled recombinant Aβ42 as TFA 
(trifluoroacetic acid) film from rPeptide (Bogart, Georgia, USA). Solutions were prepared in 
fresh MilliQ-water.  
Preparation of Aβ42 peptide stocks 
To ensure homogenous preparation of the Aβ42 peptide, 1 mg of recombinant peptide HFIP 
or TFA film was distributed in 50 µg aliquots. All peptides were aliquotted with the same 
procedure. After addition of 200 µL HFIP to 1 mg peptide, the solution was shortly sonicated, 
transferred into a Protein LoBind tube (Eppendorf, Hamburg, Germany), and the solvent was 
evaporated with a constant stream of nitrogen. The peptide film was resuspended in 1 ml of 
HFIP and, after short vortexing and sonication, dispensed in 50 µg aliquots. HFIP was 
evaporated under a stream of nitrogen, aliquots were snap-frozen, and stored at -80 ˚C until 
use as described previously (Wood et al., 1996; Stine et al., 2003). 
Preparation of fresh Aβ42 working solution 
For assays, one Aβ42 peptide aliquot was dissolved in 44.4 µl 10 mM NaOH, pH 12, to yield 
a stock solution of approximately 250 µM. The aliquot was vortexed, sonicated, vortexed 
again shortly, spun down and placed on ice until use. The resuspension of the Aβ1-42 film in 
10 mM sodium hydroxide was adapted from Teplow et al. (2006). The low NaOH 
concentration reassured the rapid pH neutralization to 7.4 upon dilution into the experimental 
buffer (Teplow, 2006) .  
 7 
The concentration of the Aβ42 solution was determined via absorbance at λ=280 nm 
measured with NanoDrop UV/Vis spectrophotometer (NanoDrop Technologies, Wilmington 
Delaware, USA). Concentration was calculated using a molar extinction coefficient of ε=1730 
M-1cm-1 (Finder et al., 2010). 
Thioflavin T aggregation assays 
To study amyloid fibril formation, 5 µM Aβ42 peptide was mixed with 50 µM Thioflavin T 
(ThT) in 10 mM sodium phosphate solution, 500 mM NaCl, and 0.1 mM HCl to a final volume 
of 100 µl. Different concentrations of ZnCl2, CuCl2 and homocysteine were added to selected 
samples after 0 or 120 minutes of measurement, respectively. Samples were incubated in a 
flat bottom microtiter plate, and the increase in ThT fluorescence was measured via top-
beam irradiation (λ Ex=450 nm, λ Em=510nm) with a lamp energy of 5000 (arbitrary unit) and a 
counting time of 0.1 seconds by Berthold Mithras LB 940 (Berthold Technologies GmbH, 
Regensdorf, Switzerland). Values were recorded every 2 minutes with constant orbital 
shaking at slow speed between the measurements. Temperature was controlled to 30 ˚C. 
                
Cytotoxicity                                
Rat primary cortical neuron cultures were prepared as described (Finder et al., 2010). 
Neurons were plated in Neurobasal media (GIBCO, Invitrogen, Basel, Switzerland) with B-27 
supplement (GIBCO) and L-glutamine (GIBCO) on poly-L-ornithine pre-coated 96-well plates 
at a density of approximately 10,000 cells per well. Cultures were maintained in a humidified 
7% CO2 incubator. Primary cortical neuron cultures were treated with Aβ-fibrils on day 6 in 
vitro. For cytotoxicity assessment, aggregation reactions were performed with 10 times 
higher concentrations and in the absence of ThT.  ThT does not affect aggregation kinetics, 
but influences cytotoxicity measurements (Finder et al., 2010). Otherwise reaction 
parameters were as described above.  
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After reaching aggregation plateau (after 3 hours), fibril suspensions were transferred in 1:10 
(v/v) ratio in relation to cell culture medium in the wells. Final concentrations on the cells 
were: 5 µM Aβ, 5 µM CuCl2 and 50 µM homocysteine. Reaction mixture without Aβ, CuCl2 or 
homocysteine was used as negative control. Just before treatment with diluted fibrils, half of 
the culture medium on cells was aspirated and replaced with fresh Neurobasal medium. 
Assays were performed minimum as triplicates. After 72 hours cell viability was quantified by 
a colorimetric MTT-(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Keskitalo 
et al., 2007). Briefly, treatment medium was removed from cells and replaced by Neurobasal 
medium with MTT. After incubation for 2 hours, lysis buffer (10% SDS, 10 mM HCl) was 
added for the incubation of cell cultures at 37 °C overnight. Absorbance was measured on 
the next day (Berthold Mithras LB 940, Berthold Technologies GmbH), and relative survival 
to control (reaction mixture without Aβ, CuCl2 or Hcy) was calculated.  
Cell morphology by immunofluorescent staining 
Approximately 100,000 rat primary cortical neurons were seeded in 24-well plates onto glass 
coverslips pre-coated with poly-L-ornithine in water. On in vitro day 6, a 24h-incubation with 
the 1:10 diluted fibrils was started. As in the MTT-assay, aggregation reactions were 
performed with 10 times higher reaction concentration and without ThT, half of the culture 
medium on cells was aspirated just before adding the aggregates. Due to the aggregation 
assay results and the physiologically occurring homocysteine levels, we chose samples 
incubated with 5 µM Aβ, 5 µM CuCl2 and 50 µM homocysteine to be shown in the results. 
Cells were stained minimum as duplicates. 5 µM non-fibrillar Aβ42 was used as a control.   
After incubation with the fibrils the cells were fixed for 15 minutes at room temperature with 
4% paraformaldehyde in PBS. The coverslips were rinsed with PBS, and washed three times 
with 0.05% Triton X-100 in TBS for 10 minutes each. After blocking with 5% goat serum 
(Millipore, Zug, Switzerland), 5% horse serum (GIBCO) and 0.2% Triton X-100 in TBS for 60 
minutes, the coverslips were incubated with primary antibodies in blocking buffer (anti-MAP2 
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1:1500, Synaptic Systems, Germany; 1:100 anti-human APP 6E10, Covance, Princeton, 
New Jersey, USA) in a humidified chamber overnight at 4 °C. On the following day coverslips 
were washed three times with 0.05% Triton X-100 in TBS for 10 minutes each, blocked for 
30 minutes at room temperature in blocking solution, and incubated with 1:300 diluted 
secondary antibodies (anti-rabbit Alexa488 (Invitrogen) and anti-mouse Cy3 (Jackson 
ImmunoResearch, West Grove, Pennsylvania, USA)) in blocking buffer for 2 hours at room 
temperature. After washing, cell nuclei were stained with DAPI (2-(4-amidinophenyl)-1H-
indole-6-carboxamidine), and coverslips were mounted on glass slides with Hydromount 
(Chemie Brunschwig, Basel, Switzerland). Staining was examined using a Zeiss ImagerZ1 
microscope (Zeiss, Oberkochen, Germany). All images were taken with a 20x objective.           
Negative-stain electron microscopy of aggregates                   
Aliquots of the aggregation reactions without ThT were analyzed, when plateau was readily 
reached after 4 hour agitation at 30 °C. 3 µl of each sample was adsorbed to 300 mesh 
carbon-coated copper grids for 1 minute and stained with 2% uranyl acetate in water for 15 
seconds three times. After staining grids were washed with water and allowed to dry before 
transmission electron microscopy (TEM). TEM was performed on a Philips CM 12 
microscope at 100 MeV.  
Statistics 
Statistical analysis was run using IBM SPSS Statistics 20 (IBM, Armonk, New York, USA), 
and significance was calculated using one-way ANOVA with Bonferroni’s post hoc test for 
multiple comparisons. Statistical significance was considered as p<0.05.  
All experiments were repeated three times with n≥3 samples for each experimental condition. 
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Results 
Homocysteine and Aβ42 compete for CuCl2, but not for ZnCl2, in ThT aggregation assay 
We established a microtiter plate format ThT aggregation assay for fast and reproducible 
monitoring of Aβ42 fibrillization in the presence of Hcy and the transition metals copper and 
zinc. As previously reported, copper and zinc inhibited the formation of ThT reactive beta-
sheet structures of amyloid-beta (Yoshiike et al., 2001; House et al., 2004). In our 
experiments ZnCl2 reduced Aβ42 fibrillization by extending the lag phase, slightly decreasing 
the slope, and diminishing the final plateau (Fig. 1a). CuCl2 (5 µM) completely prevented 
Aβ42 (5 µM) fibrillization (Fig. 1a). Homocysteine alone at increasing concentrations had no 
effect on Aβ fibril formation (Fig. 1b), but concentration-dependently reduced the inhibitory 
effect of CuCl2 on Aβ42 fibrillization (Fig. 1c). No such interaction on Aβ42 aggregation was 
observed between homocysteine and ZnCl2 (Fig. 1d).  
Hcy does not alter Aβ42 fibril morphology 
To decide whether homocysteine or copper have qualitative effects on Aβ aggregation, we 
analyzed the morphology of the aggregates of 5 µM Aβ42, 5 µM Aβ42 plus 50 µM 
homocysteine and 5 µM Aβ42 plus 5 µM CuCl2 by TEM after 4 hours aggregation (Fig. 2). 
TEM images confirmed the observations from ThT aggregation assays that homocysteine 
alone does not alter Aβ42 fibrillization, as the Aβ42 fibrils formed in the presence of 
homocysteine were alike to fibrils formed without homocysteine showing a high number of 
mature fibrils (Fig. 2a, b). In the presence of CuCl2, only few aggregates were found with 
decreased fibril length and complexity. (Fig. 2c).   
Toxicity of Aβ42 fibrils is increased in the presence of CuCl2 and decreased in the presence 
of homocysteine or homocysteine plus CuCl2  
To be able to conclude whether cytotoxicity of mixtures of copper, homocysteine and Aβ is 
caused by changes in the fibrillar status of Aβ42, we examined the cytotoxic effects of CuCl2, 
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homocysteine and the two together without Aβ42 (Fig. 3a). Rat primary cortical neurons 
were treated on day 6 in vitro for 72 hours with increasing concentrations of CuCl2 (0.5-5.0 
µM), homocysteine (5-50 µM) or CuCl2 plus homocysteine in incubation mixtures previously 
incubated for 4 hours at 30 °C. No significant toxicity was observed in neurons treated with 
the selected concentrations of CuCl2 or homocysteine alone. In line with previous results, the 
co-incubation of homocysteine plus CuCl2, i.e. with homocysteine/copper-complexes, 
showed a concentration-dependent toxicity (White et al., 2001; Linnebank et al., 2006).   
Next we studied the toxicity of Aβ42 fibrils formed in the presence of CuCl2, homocysteine or 
both (Fig. 3b).  Viability of primary neurons decreased to 40% after 72 h incubation with 5 
µM Aβ42 forming fibrils alone. Additional presence of 50 µM homocysteine or 5 µM CuCl2 
plus 50 µM homocysteine resulted in a slightly higher viability of 50%. 5 µM Aβ42 incubated 
in the presence of 5 µM CuCl2 showed a significant increase in toxicity reducing cell viability 
to 25%. The same viability was observed after incubation with 5 µM monomeric Aβ. This 
shows that most likely CuCl2 induces the formation of lower order oligomers or amorphous 
aggregates of Aβ that have high cytotoxicity, whereas homocysteine diminishes this effect 
and does not obviously contribute to cytotoxicity itself under the selected experimental 
conditions.   
Observations from cytotoxicity studies were confirmed by morphological analysis of neurons 
treated with Aβ42 aggregates collected after 4 hours of aggregation without ThT (Fig. 3c). 
Cells incubated with 5 µM Aβ42 plus 5 µM CuCl2 were shrunken and presented fewer 
neurites, resembling the morphology of cells treated with 5 µM monomeric Aβ42. In both, 
Aβ42 plus CuCl2 and monomeric Aβ42 treated cells, also anti-APP staining patterns were 
similar visualizing fewer and smaller amyloid plaque-like structures. Aβ42-stainings in other 
treatment conditions were similar to each other. Vehicle (without Aβ42) serving as a negative 
control for anti-APP staining showed no such effects.  
CuCl2 has limited effects on the aggregation of H6A mutated Aβ42    
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Fibrillization of His6Ala-mutated Aβ42 (H6A), which has low affinity to copper (Sacco et al., 
2012), was studied to examine the specificity of copper induced inhibition of Aβ42 
aggregation. Homocysteine only caused a minor concentration-dependent reduction in the 
maximum of ThT fluorescence in H6A fibrillization, which might have been due to unspecific 
variation in the ThT signal (Fig. 4a). At homocysteine concentrations higher than 50 µM, 
aggregation curves remained unchanged. Addition of 5 µM CuCl2 to the aggregation reaction 
containing 5 µM H6A inhibited its fibrillization leading to a longer lag phase, a decreased 
slope and plateau. Nonetheless, CuCl2 was not able to completely prevent H6A fibrillization 
(Fig. 4b). The effect of CuCl2 on H6A was thus decreased compared to its effects on wild-
type peptides. Increasing concentrations of homocysteine (10-100 µM) in the aggregation 
reaction of 5 µM H6A plus 5 µM CuCl2 reversed the inhibitory effect of CuCl2 on H6A 
fibrillization (Fig. 4b). The concentration of homocysteine needed to restore H6A fibril 
formation was smaller than in the case of wild-type Aβ42. As H6A has a lower affinity to 
copper than Aβ42, this underscores that there is a competition in binding of copper between 
Aβ42 and homocysteine as underlying mechanism of the interaction of homocysteine and 
copper on Aβ fibrillization. The increase in ThT fluorescence is specific to the formation of 
cross-pleated β-sheets. Accordingly, ThT fluorescence of incubation mixtures containing 
scrambled Aβ42 (ScAβ), a peptide derivative of Aβ42 that does not form fibrils, did not differ 
after addition of either 5 µM CuCl2, or 50 µM homocysteine or 5 µM CuCl2 plus 50 µM 
homocysteine confirming that the above described results did not result from artefacts 
induced by homocysteine or copper in the incubation mixtures (Fig. 4c).  
Toxicity of Aβ42, H6A and ScAβ to primary cortical neurons 
In primary neuron cultures, fibrils of 5 µM H6A, formed either in the absence or presence of 5 
µM CuCl2, 50 µM homocysteine, or a combination of both, each reduced cell viability to 
approximately 60% after 72 h incubation (Fig. 4d). Viability of neurons treated with 5 µM 
ScAβ, incubated in the absence or presence of 5 µM CuCl2, 50 µM homocysteine or both, 
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remained at approximately 90%. The overall toxicity of the H6A was significantly higher than 
the one of ScAβ, but lower than of Aβ42.     
Addition of CuCl2 to already aggregated samples untangled Aβ42 fibrils 
To study whether copper supplementation could be used to revert aggregation, we 
performed a simple aggregation assay in which CuCl2 was added to an already fibrillized 
sample of either Aβ42 alone or of Aβ42 incubated in the presence of 15 µM or 50 µM 
homocysteine. We selected these homocysteine concentrations as they define the lower 
range of homocysteine plasma concentrations in mild and intermediate 
hyperhomocysteinemia, respectively (Stanger et al., 2009). 
The addition of 5 µM CuCl2 to a sample of 5 µM Aβ42 at time point 120 min drastically 
reduced ThT fluorescence, indicating untangling of Aβ42 fibrils (Fig. 5a) similar to the 
preventive effect of copper on fibrillization (Fig. 2c). Only a minor reduction in ThT 
fluorescence was observed after addition of an equal volume of water (vehicle in which 
copper had been dissolved) to already fibrillized 5 µM Aβ42 at the same time point as 
negative control (Fig. 5a-b). After addition of increasing CuCl2 concentrations (5-15 µM), 
Aβ42 fibrils that had formed in the presence of 15 µM or 50 µM homocysteine also untangled 
(Fig. 5b-c). The decrease in ThT fluorescence depended on the ratio between copper and 
homocysteine (Fig. 5b-c). ThT fluorescence remained unchanged after vehicle additions 
(Fig. 5d).  
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Discussion  
Hyperhomocysteinemia is a risk factor for AD, in which Aβ fibrillization plays an important 
role. Our study suggests that copper is a link between homocysteine and Aβ. First, via a ThT 
assay and TEM, we confirmed that in vitro CuCl2 prevents and reverts Aβ fibril formation 
(Bolognin et al.; House et al., 2004; Chen et al., 2011) (Fig. 1a-c and Fig. 5a-c). Addition of 
CuCl2 results in decreased Aβ fibril length and complexity i.e lack of higher order aggregates 
(Fig. 2c). The underlying mechanism is most likely connected to the ability of CuCl2 to 
prevent the formation of Aβ42 beta-sheets in vitro (Yoshiike et al., 2001; House et al., 2004), 
but due to the nature of ThT assay we cannot completely rule out the possibility of the 
formation of oligomers or amorphous aggregates. However, Hcy did not affect the fibrillar 
structure of Aβ as seen in ThT assay and in TEM images (Fig. 1b and Fig. 2b).  
Our ThT aggregation assay results of CuCl2 and Aβ are in-line with other published results 
with similar experimental setup. It has been presented that in experimental conditions where 
fibril formation is fast, metal ions lower concentration of free peptide and thus inhibit 
fibrillization (Tougu et al., 2009). In conditions with slow fibril formation metal ions enhance 
fibril formation by metal-induced aggregates that can turn into fibrils (Sarell et al., 2010). 
Differences in experimental setup are also greatly influencing the outcome of fibrillization 
studies. This is summarized in a recent publication by Viles, and shows multiple differences 
associated with changes in stoichiometry, used peptide preparation, concentration and study 
technique (Viles, 2012).  
Cytotoxicity experiments performed in the absence of Aβ42 showed that CuCl2 or Hcy alone 
had no effect on cell viability (Fig. 3a). In accordance to previous studies, cytotoxicity was 
elevated when cells were co-incubated with CuCl2 and Hcy, confirming the toxicity of Hcy-
copper-complexes (Fig. 3a) (White et al., 2001). In accordance with our ThT assay data and 
TEM images, toxicity of mature Aβ42 fibrils to primary neurons was high, and Aβ fibrils 
formed in the presence of Hcy and CuCl2 showed similar toxicity (Fig. 1c, Fig. 2a-c and Fig. 
3b-c). Aβ42 co-incubated in 1:1 molar ratio with CuCl2 showed the same level of toxicity as 
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monomeric Aβ42 underlining that CuCl2 effectively inhibited the formation of bigger, more 
mature fibrils during ThT aggregation assays (Fig 2c, and Fig. 3b) (House et al., 2004; Chen 
et al., 2011). Is has been reported that the fibrillar status of Aβ42 affects its cytotoxicity in 
cultured neurons: small soluble Aβ42 dimers and oligomers cause higher toxicity than bigger 
fibrillar forms (Klyubin et al., 2005; Lesne et al., 2006; Agnati et al., 2007; Ferreira et al., 
2007; Haass and Selkoe, 2007; Ono et al., 2009).  
As a certain time-span is required for Aβ preparations in contact with primary neurons to 
exert the cytotoxic properties, we cannot completely rule out that during the 72h incubation a 
modification of the Aβ species can occur. However, as a result of our Aβ ThT aggregation 
assays we observed that the addition of CuCl2 almost completely prevented the formation of 
higher order aggregates (sensitive to ThT fluorescence). As CuCl2 itself did not have a 
measurable influence on cell viability, we infer that the observed cytotoxicity is due to Aβ 
monomers and potentially aggregates of lower molecular weight, such as Aβ di- and 
oligomers, Aβ-derived diffusible ligands or protofibrils (all probably being ThT fluorescence 
negative) that may have formed during the incubation period.  
 
Copper has four coordinating ligands in human Aβ: 3N and 1O, which involve His6, His13, 
His14 and possibly Tyr10, carboxylate group of Asp1, the amide of Ala2, and the N-terminal 
amine. To date, no consensus of exact coordinating ligands exists. When single histidines 
were mutated to alanine, observed that His6 has three times higher copper binding constant 
than His13 or His14 (Hong et al., 2010). His6 also requires less conformational changes 
upon copper binding, making it more entropy-favored. His6 was concluded to be ubiquitously 
involved in copper binding, accounting for 50% of the Aβ bound Cu(II). In our experiments, 
Hcy had only minor effect on the fibril formation of H6A mutant of Aβ42 with reduced affinity 
to copper (Fig. 4a). Also the effect of CuCl2 was weaker in H6A fibrillization, and the 
concentration of Hcy needed to restore H6A fibril formation was reduced compared to wild 
type Aβ42 (Fig. 4b and Fig. 1c). This allows the speculation that the amount of mature fibrils 
i.e. higher order aggregates in this sample was higher compared to the wild type Aβ42. In 
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accordance to this, H6A fibrils also showed less pronounced cytotoxicity in the presence of 
CuCl2 (Fig. 4d). The control, scrambled Aβ42 (ScAβ), expectedly showed no fibrils in ThT-
assay (Fig. 4c). Accordingly, ScAβ was not cytotoxic and this was not influenced by 
incubation with CuCl2 or CuCl2 plus homocysteine (Fig. 4d). In ScAβ the copper binding sites 
are lost, confirming that binding of copper to Aβ was the decisive mechanism for the 
observed differences in the ThT assay and the cytotoxicity experiments of the different 
combinations. 
The addition of CuCl2 to already fibrillized Aβ led to untangling of fibrils (Fig. 5a-c). This does 
not necessarily mean that copper is relevant for Aβ fibrillization in vivo, however, mice with 
defective copper transport have decreased brain copper levels together with increased 
amounts of amyloid plaques. When these mice are crossed with Wilson’s disease mouse 
model, the offspring have increased brain copper levels, less amyloid plaques and a longer 
life span (Phinney et al., 2003). When copper sulphate was added to the drinking water of 
mice susceptible to amyloid accumulation, less accumulation was observed (Bayer et al., 
2003). In patients with mild to moderate AD, plasma copper negatively correlates with 
cognitive abilities (Pajonk et al., 2005; Kessler et al., 2006). In addition, AD patients show 
elevated serum levels of free copper (serum copper not bound to ceruloplasmin) (Squitti et 
al., 2004; Squitti et al., 2005; Squitti et al., 2006; Capo et al., 2008; Squitti et al., 2009; Squitti 
et al., 2011) while autopsy samples of hippocampus and amygdala from AD patients showed 
generally reduced copper contents (Deibel et al., 1996; Klevay, 2008).  
In contrast, in the amyloid plaques, copper concentration can be as high as 400 µM, although 
normal brain extracellular concentration is 0.2-1.7 µM (Gutteridge, 1984; Kardos et al., 1989; 
Linder and Hazegh-Azam, 1996; Lovell et al., 1998; Schumann et al., 2002; White et al., 
2004; Squitti et al., 2006). This data seems to be in contrast to our observation that CuCl2 
prevents amyloid fibril formation. However, in our experiments, CuCl2 alone prevented and 
reverted aggregation, whereas Hcy plus CuCl2 did not. Thus, it would be interesting to 
analyze whether copper in amyloid plaques of AD patients is bound to Hcy or other 
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molecules. Moreover, the inhibitory effect of CuCl2 on fibrillization was concentration-
dependent (Fig. 5b-c). Thus, one may speculate that in the copper-rich plaques of AD 
patients, copper levels may not have reached the necessary concentration.  
Serum homocysteine concentrations over 14 µM are an independent risk factor for the 
development of AD (Seshadri et al., 2002). In our study, the addition of homocysteine alone 
did not change Aβ42 fibril formation (Fig. 1b), although the addition of homocysteine slightly 
reduced Aβ42 toxicity in vitro (Fig. 3b). In co-incubation experiments, homocysteine 
concentration-dependently reduced the inhibitory effects of CuCl2 on Aβ42 fibrillization 
suggesting that homocysteine and Aβ compete for copper binding, i.e. homocysteine-bound 
copper has reduced or no effects on Aβ42 fibril formation (Fig. 1c). Two different complexes 
are possible between homocysteine and copper, showing molar ratios of 1:1 or ≤1:3 
(Apostolova et al., 2003). Similarly, the majority of the copper-Aβ complexes form with a 1:1 
stoichiometry at physiological pH (Karr et al., 2005; Syme and Viles, 2006; Tougu et al., 
2008; Faller and Hureau, 2009). For H6A, homocysteine was more effective in neutralizing 
the effect of CuCl2 on fibril formation confirming that CuCl2 is less effective in preventing 
fibrillization of this mutated peptide due to its reduced affinity to copper (Fig. 4b).  
In summary, this study shows that both homocysteine and Aβ42 bind and compete for 
copper. Copper prevents and reverts fibril formation by binding to Aβ42 and thereby 
increases Aβ toxicity. Homocysteine builds toxic complexes with copper and concentration-
dependently prevents the effects of copper on Aβ42 fibrillization. In the presence of Aβ42, 
neurotoxicity of copper is reduced giving rise to the speculation that one physiological Aβ 
function might be the prevention of copper neurotoxicity. Due to complex building, 
hyperhomocysteinemia reduces the availability of free copper, which in the light of our 
results, likely increases amyloid plaque formation. Acute presence of high copper 
concentrations untangle aggregates leading to high concentrations of mono- or oligomeric 
Aβ42-copper complexes causing marked neurotoxicity. The analysis of the interaction 
between Aβ42, copper and homocysteine in patients may lead to novel therapeutic strategies 
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in the prevention and treatment of AD.  
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Figure legends 
 
 
Figure 1: Effect of metal ions and homocysteine on Aβ42 fibrillization as observed in 
ThT-assay. Fibrillization of 5 µM Aβ42 (light grey) in the presence of A) 5 µM ZnCl2 (light 
blue) or 5 µM CuCl2 (light green), B) increasing concentrations of Hcy (5 µM - red, 10 µM - 
orange, 25 µM - dark green, 50 µM - pink, and 100 µM - dark blue), C) 5 µM Hcy (red) or 5 
µM CuCl2 (light green), or 5 µM CuCl2 together with increasing Hcy concentration (10 µM - 
orange, 25 µM - dark green, 50 µM - pink, and 100 µM - dark blue), and D) 5 µM Hcy (red) or 
5 µM ZnCl2 (light blue), or 5 µM ZnCl2 together with increasing Hcy concentration (25 µM – 
dark green, 50 µM – pink, and 100 µM – dark blue). All components were added to the 
reaction mixture directly at the beginning of the fibrillization reaction.   
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Figure 2: Visualization of Aβ42 fibrils. 110,000x transmission electron microscopy images 
of the end point products of Aβ42 fibrillization after 4 hours of aggregation at 30 ˚C. A) 5 µM 
Aβ42 alone, B) 5 µM Aβ42 + 50 µM Hcy and C) 5 µM Aβ42 + 5 µM CuCl2. Aβ42, Hcy and 
CuCl2 were all added at the beginning of the ThT-assay. Scale bar represents 100 nm.  
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Figure 3: Cell viability and morphology of rat primary cortical neurons after treatment 
with CuCl2 and Hcy in the absence or presence of Aβ42.  Aggregations for viability and 
morphology studies were performed identically to previous aggregation assays, but lacking 
ThT due to its cytotoxicity.  
After 4 hour agitation, samples were subsequently collected for the assessments. A) Primary 
neurons were incubated for 72 hours with increasing µM concentrations of CuCl2 (dark grey), 
CuCl2 + Hcy (light grey), or Hcy (stripes) without Aβ42, to study their individual cytotoxicity. 
Control sample (aggregation assay reaction mixture) is visualized in the white column. B) 
Effect of CuCl2 and Hcy on Aβ42-induced toxicity. 5 µM Aβ42; 5 µM Aβ42 + 5 µM CuCl2; 5 
µM Aβ42 + 5 µM CuCl2 + 50 µM Hcy; 5 µM Aβ42 + 50 µM Hcy were incubated on the cells 
for 72 hours. As controls non-fibrillar 5 µM Aβ42 (MonoAb) and aggregation assay reaction 
mixture without Aβ42 were used. All values are relative to reaction mixture control sample ± 
S.D. C) Immunofluorescent staining of primary cortical neurons after 24 hours incubation. 
Antibody against neuronal marker, MAP2 (green), visualizes the changes of neuronal 
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morphology; whereas anti-human APP (red) shows the Aβ aggregates and DAPI (blue) the 
cell nuclei. Concentrations were as indicated in B).  Scalebar represents 100 µm.   
 
 
 
Figure 4: Fibrillization of H6A mutated Aβ42 and scrambled Aβ42 in ThT-aggregation 
assay, and their cytotoxicity in rat primary cortical neurons. Fibrillization of 5 µM H6A 
mutated Aβ42 (H6A; light blue) A) in the presence of increasing concentrations of Hcy (10 
µM - orange, 25 µM - dark green, 50 µM - pink, and 100 µM - dark blue), B) with 5 µM CuCl2 
and increasing concentrations of Hcy (10 µM - orange, 25 µM - dark green, 50 µM - pink, and 
100 µM - dark blue). C) 5 µM scrambled Aβ42 (ScAβ; light blue) does not form fibrils when 
incubated alone or together with 5 µM CuCl2 or 5 µM CuCl2 + 50 µM Hcy or 50 µM Hcy. D) 
Cell viability of rat primary neurons after 72h incubation with H6A fibrils or ScAβ incubated 
under same conditions. Samples from aggregation assay without ThT, but with CuCl2, Hcy 
or both, were collected at the plateau after 4 hour incubation. Concentrations were 5 µM H6A 
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or ScAβ; 5 µM H6A or ScAβ + 5 µM CuCl2; 5 µM H6A or ScAβ + 5 µM CuCl2 + 50 µM Hcy; 
5 µM H6A or ScAβ + 50 µM Hcy. As a control non-fibrillar 5 µM H6A or ScAβ (Mono) and 
aggregation assay reaction mixture without H6A or ScAβ were used. All values are relative to 
reaction mixture control sample ± S.D. 
 
 
 
Figure 5: Aβ42 fibrils untangle by addition of CuCl2 at timepoint 120 min in ThT 
aggregation assay. A-C) CuCl2 was added at the point indicated by an asterisk. A) Addition 
of 5 µM CuCl2 caused a drastic reduction in ThT fluorescence when added to an aggregation 
reaction of 5 µM Aβ42 (dark green). Water, in equal volume, (H2O, dark grey) did not induce 
reduction in ThT fluorescence. As controls, aggregation of 5 µM Aβ42 (light grey) and 5 µM 
Aβ42 + 5 µM CuCl2, added at the beginning of the reaction (light green), are shown. B) 
 24 
When Aβ42 fibrils are formed in the presence of 15 µM Hcy (orange), their untangling after 
CuCl2 addition depends on the molar ratio between CuCl2 and Hcy (5 µM CuCl2 - light 
green and 15 µM CuCl2 - dark green). Water added in equal volumes to CuCl2 did not 
change ThT fluorescence (light and dark blue). As a control aggregation of 5 µM Aβ42 (light 
grey) is shown. C) After CuCl2 addition Aβ42 fibrils that were previously formed in high Hcy 
concentration (5 µM Aβ42+ 50 µM Hcy) untangled. Degree of untangling was dependent on 
the molar ratio of Aβ42 to added CuCl2 and on the molar ratio of Hcy to added CuCl2 
concentration (5 CuCl - light green, 15 µM CuCl2 - dark green, 20 µM CuCl2 - purple, 25 µM 
CuCl2 - light pink, 30 µM CuCl2 - light blue, and 50 µM CuCl2 - dark blue). D) Water addition 
at timepoint 120 min did not induce changes in the ThT fluorescence of the reactions of 5 µM 
Aβ42 + 50 µM Hcy. Water was added in equal volumes as CuCl2 in Fig.5C.        
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